New study tests paliperidone for schizophrenia in 505 bangladeshi adults

NCT ID NCT07153835

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 28 times

Summary

This study will test the safety and effectiveness of an extended-release medication called paliperidone in 505 adults with schizophrenia in Bangladesh. Participants will take the medication for 12 weeks, and researchers will track changes in symptoms and side effects. The goal is to see if this treatment helps control the condition better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sher-E-Bangla Medical College Hospital

    Barishal, 8200, Bangladesh

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.